H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Sell rating on Sarepta Therapeutics (NASDAQ: SRPT) and lowered price target to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE